Treatment with hif-1α antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 940-949

  Jacoby, Jörg J ^a   Erez, Baruch ^a   Korshunova, Maria V ^a   Williams, Ryan R ^a   Furutani, Kazuhisa ^a   Takahashi, Osamu ^a   Kirkpatrick, Lynn ^b   Lippman, Scott M ^a   Powis, Garth ^a   O'Reilly, Michael S ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Oncothyreon Inc   (United States)

Author keywords

HIF 1 ; Hypoxia; Lung cancer; Orthotopic model; PX 478

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; CYCLOPHOSPHAMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; 2 AMINO 3 (4' N,N BIS(2 CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N OXIDE; 2-AMINO-3-(4'-N,N-BIS(2-CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N-OXIDE; HIF1A PROTEIN, MOUSE; MUSTARD GAS DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MEDIASTINUM METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; APOPTOSIS; DISEASE COURSE; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; MUSTARD COMPOUNDS; PHENYLPROPIONATES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 77954425345     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181dc211f     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and pac-litaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899. (Pubitemid 46300205)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537. (Pubitemid 41540110)
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
6. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-859.
7. Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 2008;33:526-534.
8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
9. Chan DA, Krieg AJ, Turcotte S, et al. HIF gene expression in cancer therapy. Methods Enzymol 2007;435:323-345.
10. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85:881-890. (Pubitemid 33010557)
11. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. DEC1 (STRA13) protein expression relates to hypoxia-inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol 2003;200:222-228. (Pubitemid 36748031)
12. Enatsu S, Iwasaki A, Shirakusa T, et al. Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocar-cinomas of the lung. Eur J Cardiothorac Surg 2006;29:891-895. (Pubitemid 43728579)
13. Hung JJ, Yang MH, Hsu HS, et al. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009;64:1082-1089.
14. Ioannou M, Papamichali R, Kouvaras E, et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 2009;187:321-329.
15. Karetsi E, Kerenidi T, Ioannou M, et al. Clinical significance of hypoxia inducible factor-1 alpha and VEGF expression in lung cancer. European Respiratory Society (ERS) Annual Meeting, Vienna, 2009; Abstract 283.
16. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-5569.
17. Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-induc-ible factor-1alpha. Mol Cancer Ther 2004;3:233-244. (Pubitemid 39193698)
18. Yano S, Nokihara H, Hanibuchi M, et al. Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice. Oncol Res 1997;9:573-579. (Pubitemid 127787907)
19. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci US A 1993;90:4304-4308.
20. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003;9:5532-5539. (Pubitemid 37499472)
21. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007;6:471-483. (Pubitemid 46332449)
22. Palayoor ST, Mitchell JB, Cerna D, et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008;123:2430-2437.